Evolve Biologics® Completes Phase III Adult and Pediatric Trials for Plasmacap™ Ig (Intravenous Immunoglobulin)
Mississauga, ON, Canada (February 9, 2021) – Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced that it has successfully completed its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”), conducted at 12 study centers across the U.S. and Canada. PlasmaCap IG is an investigational IVIG replacement therapy for adult and pediatric patients with primary immune deficiency disease (“PIDD”).